Amalgamated Bank Sells 417 Shares of Solventum Co. (NYSE:SOLV)

Amalgamated Bank lessened its holdings in shares of Solventum Co. (NYSE:SOLV) by 1.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,768 shares of the company’s stock after selling 417 shares during the quarter. Amalgamated Bank’s holdings in Solventum were worth $1,768,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Modus Advisors LLC bought a new stake in Solventum during the fourth quarter worth approximately $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum in the fourth quarter worth $26,000. Crews Bank & Trust bought a new stake in shares of Solventum during the 4th quarter worth $32,000. True Wealth Design LLC grew its stake in Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after buying an additional 471 shares during the last quarter. Finally, Prospera Private Wealth LLC bought a new position in Solventum in the 3rd quarter worth $35,000.

Solventum Trading Down 4.7 %

Shares of Solventum stock opened at $79.56 on Monday. The company’s fifty day moving average price is $72.51 and its two-hundred day moving average price is $70.05. The firm has a market capitalization of $13.74 billion and a PE ratio of 28.93. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on SOLV shares. Morgan Stanley raised their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday. Mizuho began coverage on shares of Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price for the company. Finally, Piper Sandler raised their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, Solventum has a consensus rating of “Hold” and a consensus price target of $74.71.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.